Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 142

1.

Retinoids Repress Human Cardiovascular Cell Calcification With Evidence for Distinct Selective Retinoid Modulator Effects.

Rogers MA, Chen J, Nallamshetty S, Pham T, Goto S, Muehlschlegel JD, Libby P, Aikawa M, Aikawa E, Plutzky J.

Arterioscler Thromb Vasc Biol. 2019 Dec 19:ATVBAHA119313366. doi: 10.1161/ATVBAHA.119.313366. [Epub ahead of print]

PMID:
31852220
2.

Bridging the Gap for Patients with Diabetes and Cardiovascular Disease Through Cardiometabolic Collaboration.

Chang LS, Vaduganathan M, Plutzky J, Aroda VR.

Curr Diab Rep. 2019 Dec 4;19(12):157. doi: 10.1007/s11892-019-1260-0. Review.

PMID:
31802265
3.

Diabetes Is Associated With Worse Long-term Outcomes in Young Adults After Myocardial Infarction: The Partners YOUNG-MI Registry.

Divakaran S, Singh A, Biery D, Yang J, DeFilippis EM, Collins BL, Ramsis M, Qamar A, Hainer J, Klein J, Cannon CP, Polk DM, Plutzky J, Nasir K, Januzzi JL, Di Carli MF, Bhatt DL, Blankstein R.

Diabetes Care. 2019 Sep 23. pii: dc190998. doi: 10.2337/dc19-0998. [Epub ahead of print]

PMID:
31548242
4.

A Roadmap on the Prevention of Cardiovascular Disease Among People Living With Diabetes.

Mitchell S, Malanda B, Damasceno A, Eckel RH, Gaita D, Kotseva K, Januzzi JL, Mensah G, Plutzky J, Prystupiuk M, Ryden L, Thierer J, Virani SS, Sperling L.

Glob Heart. 2019 Sep;14(3):215-240. doi: 10.1016/j.gheart.2019.07.009. No abstract available.

PMID:
31451236
5.

The selective peroxisome proliferator-activated receptor alpha modulator (SPPARMα) paradigm: conceptual framework and therapeutic potential : A consensus statement from the International Atherosclerosis Society (IAS) and the Residual Risk Reduction Initiative (R3i) Foundation.

Fruchart JC, Santos RD, Aguilar-Salinas C, Aikawa M, Al Rasadi K, Amarenco P, Barter PJ, Ceska R, Corsini A, Després JP, Duriez P, Eckel RH, Ezhov MV, Farnier M, Ginsberg HN, Hermans MP, Ishibashi S, Karpe F, Kodama T, Koenig W, Krempf M, Lim S, Lorenzatti AJ, McPherson R, Nuñez-Cortes JM, Nordestgaard BG, Ogawa H, Packard CJ, Plutzky J, Ponte-Negretti CI, Pradhan A, Ray KK, Reiner Ž, Ridker PM, Ruscica M, Sadikot S, Shimano H, Sritara P, Stock JK, Su TC, Susekov AV, Tartar A, Taskinen MR, Tenenbaum A, Tokgözoğlu LS, Tomlinson B, Tybjærg-Hansen A, Valensi P, Vrablík M, Wahli W, Watts GF, Yamashita S, Yokote K, Zambon A, Libby P.

Cardiovasc Diabetol. 2019 Jun 4;18(1):71. doi: 10.1186/s12933-019-0864-7. Review.

6.

Familial Hypercholesterolemia Among Young Adults With Myocardial Infarction.

Singh A, Gupta A, Collins BL, Qamar A, Monda KL, Biery D, Lopez JAG, de Ferranti SD, Plutzky J, Cannon CP, Januzzi JL Jr, Di Carli MF, Nasir K, Bhatt DL, Blankstein R.

J Am Coll Cardiol. 2019 May 21;73(19):2439-2450. doi: 10.1016/j.jacc.2019.02.059.

PMID:
31097165
7.

The BD2 domain of BRD4 is a determinant in EndoMT and vein graft neointima formation.

Zhang M, Wang B, Urabe G, Huang Y, Plutzky J, Kent KC, Guo LW.

Cell Signal. 2019 Sep;61:20-29. doi: 10.1016/j.cellsig.2019.05.005. Epub 2019 May 7.

PMID:
31075399
8.

Addressing cardiovascular risk in type 2 diabetes mellitus: a report from the European Society of Cardiology Cardiovascular Roundtable.

Cosentino F, Ceriello A, Baeres FMM, Fioretto P, Garber A, Stough WG, George JT, Grant PJ, Khunti K, Langkilde AM, Plutzky J, Rydén L, Scheen A, Standl E, Tuomilehto J, Zannad F.

Eur Heart J. 2019 Sep 7;40(34):2907-2919. doi: 10.1093/eurheartj/ehy677. No abstract available.

PMID:
30445605
9.

Efficacy and safety of alirocumab among individuals with diabetes mellitus and atherosclerotic cardiovascular disease in the ODYSSEY phase 3 trials.

Ganda OP, Plutzky J, Sanganalmath SK, Bujas-Bobanovic M, Koren A, Mandel J, Letierce A, Leiter LA.

Diabetes Obes Metab. 2018 Oct;20(10):2389-2398. doi: 10.1111/dom.13384. Epub 2018 Jul 2.

10.

Distribution and Performance of Cardiovascular Risk Scores in a Mixed Population of HIV-Infected and Community-Based HIV-Uninfected Individuals in Uganda.

Muiru AN, Bibangambah P, Hemphill L, Sentongo R, Kim JH, Triant VA, Bangsberg DR, Tsai AC, Martin JN, Haberer JE, Boum Y 2nd, Plutzky J, Hunt PW, Okello S, Siedner MJ.

J Acquir Immune Defic Syndr. 2018 Aug 1;78(4):458-464. doi: 10.1097/QAI.0000000000001696.

11.

Predictors of a successful statin reattempt after an adverse reaction.

Zhang H, Plutzky J, Ge W, Shubina M, Turchin A.

J Clin Lipidol. 2018 May - Jun;12(3):643-651. doi: 10.1016/j.jacl.2018.02.005. Epub 2018 Feb 14.

PMID:
29567104
12.

Lipids in RA: Is Less Not Necessarily More?

Plutzky J, Liao KP.

Curr Rheumatol Rep. 2018 Feb 21;20(2):8. doi: 10.1007/s11926-018-0715-7. Review.

13.

BET bromodomain proteins regulate enhancer function during adipogenesis.

Brown JD, Feldman ZB, Doherty SP, Reyes JM, Rahl PB, Lin CY, Sheng Q, Duan Q, Federation AJ, Kung AL, Haldar SM, Young RA, Plutzky J, Bradner JE.

Proc Natl Acad Sci U S A. 2018 Feb 27;115(9):2144-2149. doi: 10.1073/pnas.1711155115. Epub 2018 Feb 14.

14.

Sodium/Glucose Cotransporter 2 Inhibitors in Patients With Diabetes Mellitus and Chronic Kidney Disease: Turning the Page.

Plutzky J, Bakris G.

Circulation. 2018 Jan 9;137(2):130-133. doi: 10.1161/CIRCULATIONAHA.117.031422. No abstract available.

PMID:
29311346
15.

Adiponectin concentration data improve the estimation of atherosclerotic risk in normal and in overweight subjects.

Bertolami A, de Lima-Júnior JC, Cintra RM, Carvalho LS, Gonzaga CC, Sulzbach ML, Petisco ACGP, Barbosa JEM, Faludi AA, Plutzky J, Bertolami MC, Sposito AC.

Clin Endocrinol (Oxf). 2018 Mar;88(3):388-396. doi: 10.1111/cen.13540. Epub 2018 Jan 10.

PMID:
29280189
16.

Cardiovascular Risk and Statin Eligibility of Young Adults After an MI: Partners YOUNG-MI Registry.

Singh A, Collins BL, Gupta A, Fatima A, Qamar A, Biery D, Baez J, Cawley M, Klein J, Hainer J, Plutzky J, Cannon CP, Nasir K, Di Carli MF, Bhatt DL, Blankstein R.

J Am Coll Cardiol. 2018 Jan 23;71(3):292-302. doi: 10.1016/j.jacc.2017.11.007. Epub 2017 Nov 12.

17.

Continued Statin Prescriptions After Adverse Reactions and Patient Outcomes: A Cohort Study.

Zhang H, Plutzky J, Shubina M, Turchin A.

Ann Intern Med. 2017 Aug 15;167(4):221-227. doi: 10.7326/M16-0838. Epub 2017 Jul 25.

PMID:
28738423
18.

Correction: Adipocyte arrestin domain-containing 3 protein (Arrdc3) regulates uncoupling protein 1 (Ucp1) expression in white adipose independently of canonical changes in β-adrenergic receptor signaling.

Carroll SH, Zhang E, Wang BF, LeClair KB, Rahman A, Cohen DE, Plutzky J, Patwari P, Lee RT.

PLoS One. 2017 Jul 10;12(7):e0181492. doi: 10.1371/journal.pone.0181492. eCollection 2017.

19.

Adipocyte arrestin domain-containing 3 protein (Arrdc3) regulates uncoupling protein 1 (Ucp1) expression in white adipose independently of canonical changes in β-adrenergic receptor signaling.

Carroll SH, Zhang E, Wang BF, LeClair KB, Rahman A, Cohen DE, Plutzky J, Patwari P, Lee RT.

PLoS One. 2017 Mar 14;12(3):e0173823. doi: 10.1371/journal.pone.0173823. eCollection 2017. Erratum in: PLoS One. 2017 Jul 10;12 (7):e0181492.

20.

Risk factors for lack of statin therapy in patients with diabetes and coronary artery disease.

Zhang H, Plutzky J, Shubina M, Turchin A.

J Clin Lipidol. 2016 Nov - Dec;10(6):1406-1413. doi: 10.1016/j.jacl.2016.09.010. Epub 2016 Sep 17.

PMID:
27919358
21.

Inhibition of BET bromodomain attenuates angiotensin II induced abdominal aortic aneurysm in ApoE-/- mice.

Duan Q, Mao X, Liao C, Zhou H, Sun Z, Deng X, Hu Q, Qi J, Zhang G, Huang H, Plutzky J, Yang T.

Int J Cardiol. 2016 Nov 15;223:428-432. doi: 10.1016/j.ijcard.2016.08.238. Epub 2016 Aug 14.

PMID:
27544600
22.

Epigenetic Changes in Diabetes and Cardiovascular Risk.

Keating ST, Plutzky J, El-Osta A.

Circ Res. 2016 May 27;118(11):1706-22. doi: 10.1161/CIRCRESAHA.116.306819. Review.

23.

Drivers of the Sex Disparity in Statin Therapy in Patients with Coronary Artery Disease: A Cohort Study.

Zhang H, Plutzky J, Shubina M, Turchin A.

PLoS One. 2016 May 5;11(5):e0155228. doi: 10.1371/journal.pone.0155228. eCollection 2016.

24.

Extensive metabolic disorders are present in APC(min) tumorigenesis mice.

Liu Z, Xiao Y, Zhou Z, Mao X, Cai J, Xiong L, Liao C, Huang F, Liu Z, Ali Sheikh MS, Plutzky J, Huang H, Yang T, Duan Q.

Mol Cell Endocrinol. 2016 May 15;427:57-64. doi: 10.1016/j.mce.2016.03.004. Epub 2016 Mar 4.

PMID:
26948948
25.

Brown Fat and Browning for the Treatment of Obesity and Related Metabolic Disorders.

Kim SH, Plutzky J.

Diabetes Metab J. 2016 Feb;40(1):12-21. doi: 10.4093/dmj.2016.40.1.12. Review.

26.

Super enhancers at the miR-146a and miR-155 genes contribute to self-regulation of inflammation.

Duan Q, Mao X, Xiao Y, Liu Z, Wang Y, Zhou H, Zhou Z, Cai J, Xia K, Zhu Q, Qi J, Huang H, Plutzky J, Yang T.

Biochim Biophys Acta. 2016 Apr;1859(4):564-71. doi: 10.1016/j.bbagrm.2016.02.004. Epub 2016 Feb 5.

PMID:
26855180
27.

Effects of statin therapy on coronary artery plaque volume and high-risk plaque morphology in HIV-infected patients with subclinical atherosclerosis: a randomised, double-blind, placebo-controlled trial.

Lo J, Lu MT, Ihenachor EJ, Wei J, Looby SE, Fitch KV, Oh J, Zimmerman CO, Hwang J, Abbara S, Plutzky J, Robbins G, Tawakol A, Hoffmann U, Grinspoon SK.

Lancet HIV. 2015 Feb;2(2):e52-63. doi: 10.1016/S2352-3018(14)00032-0. Epub 2015 Jan 9.

28.

Differential role of an NF-κB transcriptional response element in endothelial versus intimal cell VCAM-1 expression.

Milstone DS, Ilyama M, Chen M, O'Donnell P, Davis VM, Plutzky J, Brown JD, Haldar SM, Siu A, Lau AC, Zhu SN, Basheer MF, Collins T, Jongstra-Bilen J, Cybulsky MI.

Circ Res. 2015 Jul 3;117(2):166-77. doi: 10.1161/CIRCRESAHA.117.306666. Epub 2015 Jun 1.

29.

Statin eligibility and cardiovascular risk burden assessed by coronary artery calcium score: comparing the two guidelines in a large Korean cohort.

Rhee EJ, Park SE, Oh HG, Park CY, Oh KW, Park SW, Blankstein R, Plutzky J, Lee WY.

Atherosclerosis. 2015 May;240(1):242-9. doi: 10.1016/j.atherosclerosis.2015.03.006. Epub 2015 Mar 7.

PMID:
25818250
30.

Emerging epigenetic maps in atherosclerosis.

Plutzky J.

Circ Cardiovasc Genet. 2014 Oct;7(5):573-5. doi: 10.1161/CIRCGENETICS.114.000829. No abstract available.

PMID:
25518042
31.

NF-κB directs dynamic super enhancer formation in inflammation and atherogenesis.

Brown JD, Lin CY, Duan Q, Griffin G, Federation A, Paranal RM, Bair S, Newton G, Lichtman A, Kung A, Yang T, Wang H, Luscinskas FW, Croce K, Bradner JE, Plutzky J.

Mol Cell. 2014 Oct 23;56(2):219-231. doi: 10.1016/j.molcel.2014.08.024. Epub 2014 Sep 25.

32.

Association of monocyte tumor necrosis factor α expression and serum inflammatory biomarkers with walking impairment in peripheral artery disease.

Pande RL, Brown J, Buck S, Redline W, Doyle J, Plutzky J, Creager MA.

J Vasc Surg. 2015 Jan;61(1):155-61. doi: 10.1016/j.jvs.2014.06.116. Epub 2014 Aug 2.

33.

Retinaldehyde dehydrogenase 1 deficiency inhibits PPARγ-mediated bone loss and marrow adiposity.

Nallamshetty S, Le PT, Wang H, Issacsohn MJ, Reeder DJ, Rhee EJ, Kiefer FW, Brown JD, Rosen CJ, Plutzky J.

Bone. 2014 Oct;67:281-91. doi: 10.1016/j.bone.2014.07.005. Epub 2014 Jul 24.

34.

Diabetes and cardiovascular disease in older adults: current status and future directions.

Halter JB, Musi N, McFarland Horne F, Crandall JP, Goldberg A, Harkless L, Hazzard WR, Huang ES, Kirkman MS, Plutzky J, Schmader KE, Zieman S, High KP.

Diabetes. 2014 Aug;63(8):2578-89. doi: 10.2337/db14-0020.

35.

(Mis)interpreting studies on the adverse effects of statins.

Zhang H, Plutzky J, Turchin A.

BMJ. 2014 Jun 11;348:g3652. doi: 10.1136/bmj.g3652. No abstract available.

PMID:
24920686
36.

Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient-level pooled analysis of six randomized clinical trials.

Fonseca VA, Devries JH, Henry RR, Donsmark M, Thomsen HF, Plutzky J.

J Diabetes Complications. 2014 May-Jun;28(3):399-405. doi: 10.1016/j.jdiacomp.2014.01.009. Epub 2014 Jan 21.

37.

Residual macrovascular risk in 2013: what have we learned?

Fruchart JC, Davignon J, Hermans MP, Al-Rubeaan K, Amarenco P, Assmann G, Barter P, Betteridge J, Bruckert E, Cuevas A, Farnier M, Ferrannini E, Fioretto P, Genest J, Ginsberg HN, Gotto AM Jr, Hu D, Kadowaki T, Kodama T, Krempf M, Matsuzawa Y, Núñez-Cortés JM, Monfil CC, Ogawa H, Plutzky J, Rader DJ, Sadikot S, Santos RD, Shlyakhto E, Sritara P, Sy R, Tall A, Tan CE, Tokgözoğlu L, Toth PP, Valensi P, Wanner C, Zambon A, Zhu J, Zimmet P; Residual Risk Reduction Initiative (R3i).

Cardiovasc Diabetol. 2014 Jan 24;13:26. doi: 10.1186/1475-2840-13-26. Review.

38.

Impact of pre-diabetes on heart transplant outcomes in patients with advanced heart failure.

Chamarthi B, Zafrir B, Plutzky J, Givertz MM.

J Heart Lung Transplant. 2014 Feb;33(2):215-7. doi: 10.1016/j.healun.2013.10.018. Epub 2013 Oct 20. No abstract available.

39.

A diurnal serum lipid integrates hepatic lipogenesis and peripheral fatty acid use.

Liu S, Brown JD, Stanya KJ, Homan E, Leidl M, Inouye K, Bhargava P, Gangl MR, Dai L, Hatano B, Hotamisligil GS, Saghatelian A, Plutzky J, Lee CH.

Nature. 2013 Oct 24;502(7472):550-4. doi: 10.1038/nature12710.

40.

Deficiency of retinaldehyde dehydrogenase 1 induces BMP2 and increases bone mass in vivo.

Nallamshetty S, Wang H, Rhee EJ, Kiefer FW, Brown JD, Lotinun S, Le P, Baron R, Rosen CJ, Plutzky J.

PLoS One. 2013 Aug 9;8(8):e71307. doi: 10.1371/journal.pone.0071307. eCollection 2013.

41.

BET bromodomains mediate transcriptional pause release in heart failure.

Anand P, Brown JD, Lin CY, Qi J, Zhang R, Artero PC, Alaiti MA, Bullard J, Alazem K, Margulies KB, Cappola TP, Lemieux M, Plutzky J, Bradner JE, Haldar SM.

Cell. 2013 Aug 1;154(3):569-82. doi: 10.1016/j.cell.2013.07.013.

42.

Discontinuation of statins in routine care settings.

Zhang H, Plutzky J, Turchin A.

Ann Intern Med. 2013 Jul 2;159(1):75-6. doi: 10.7326/0003-4819-159-1-201307020-00022. No abstract available.

PMID:
23817716
43.

Management of low levels of high-density lipoprotein-cholesterol.

Khera AV, Plutzky J.

Circulation. 2013 Jul 2;128(1):72-8. doi: 10.1161/CIRCULATIONAHA.112.000443. Review. No abstract available.

44.

Endothelial lipase is a critical determinant of high-density lipoprotein-stimulated sphingosine 1-phosphate-dependent signaling in vascular endothelium.

Tatematsu S, Francis SA, Natarajan P, Rader DJ, Saghatelian A, Brown JD, Michel T, Plutzky J.

Arterioscler Thromb Vasc Biol. 2013 Aug;33(8):1788-94. doi: 10.1161/ATVBAHA.113.301300. Epub 2013 May 30.

45.

Discontinuation of statins in routine care settings: a cohort study.

Zhang H, Plutzky J, Skentzos S, Morrison F, Mar P, Shubina M, Turchin A.

Ann Intern Med. 2013 Apr 2;158(7):526-34. doi: 10.7326/0003-4819-158-7-201304020-00004.

46.

Modulating peroxisome proliferator-activated receptors for therapeutic benefit? Biology, clinical experience, and future prospects.

Rosenson RS, Wright RS, Farkouh M, Plutzky J.

Am Heart J. 2012 Nov;164(5):672-80. doi: 10.1016/j.ahj.2012.06.023. Epub 2012 Oct 16. Review.

47.

Fifty shades of brown: perivascular fat, thermogenesis, and atherosclerosis.

Kiefer FW, Cohen P, Plutzky J.

Circulation. 2012 Aug 28;126(9):1012-5. doi: 10.1161/CIRCULATIONAHA.112.123521. No abstract available.

48.

Retinoid metabolism and diabetes mellitus.

Rhee EJ, Plutzky J.

Diabetes Metab J. 2012 Jun;36(3):167-80. doi: 10.4093/dmj.2012.36.3.167. Epub 2012 Jun 14.

49.

NHLBI Integrated Guidelines on Cardiovascular Disease Risk Reduction: can we clarify the controversy about cholesterol screening and treatment in childhood?

de Ferranti SD, Daniels SR, Gillman M, Vernacchio L, Plutzky J, Baker AL.

Clin Chem. 2012 Dec;58(12):1626-30. doi: 10.1373/clinchem.2012.182089. Epub 2012 Jun 22. No abstract available.

PMID:
22730451
50.

The biology of atherosclerosis: general paradigms and distinct pathogenic mechanisms among HIV-infected patients.

Lo J, Plutzky J.

J Infect Dis. 2012 Jun;205 Suppl 3:S368-74. doi: 10.1093/infdis/jis201. Review.

Supplemental Content

Loading ...
Support Center